Table 1.

CGRP Effects Relevant to Cutaneous Immunity (refs)

Inhibits murine LC antigen presentation for Th1 responses (Hosoi et al. 1993, Asahina et al. 1995b, Ding et al. 2008).

Enhances murine LC antigen presentation for Th2 responses (Ding et al. 2008).

Inhibits murine LC interferon-γ-induced CXCL9 and CXCL10 production while inducing production of CCL17 and CCL22 (Ding et al. 2008).

Inhibits lipopolysaccharide-induced expression of IL-1β and IL-12 p40 by a murine LC-like cell line while enhancing IL-10 expression (Torii et al. 1997).

Inhibits stimulated NFκB signaling in murine LCs (Ding et al. 2007).

Intradermal administration inhibits immunity to Th1 dominant haptens while enhancing the response to Th2 dominant haptens in mice (Asahina et al. 1995a, Mikami et al. 2011).

Inhibits the response to inflammatory stimuli in vivo in mice, rats, hamsters and humans (Gomes et al. 2005, Raud et al. 1991, Clementi et al. 1994, Clementi et al. 1995).

Inhibits stimulated production of the chemokines CXCL1, CCL2 and CXCL8 by human dermal microvascular endothelial cells (Huang et al. 2011).

Inhibits stimulated NFκB signaling in murine dermal microvascular endothelial cells (Huang et al. 2011).

Plays in an important role in the Tie2-KC murine model of psorisiform dermatitis (Ostrowski, et al. 2011).

Inhibits human monocyte-derived LC mediated HIV-1 transmission to T cells (Ganor et al. 2013).